House Committee requests EpiPen documents from Mylan
- Banks, telecoms lead Wall Street up; another Dow record
- Western Digital (WDC) Raises Q2 Outlook
- bluebird bio (BLUE) to Offer $200M of Common Stock
- Dave & Buster's Entertainment (PLAY) Tops Q3 EPS by 11c, Raises FY Revenue Guidance
- After-Hours Stock Movers 12/06: (PLAY) (ANTH) (WDC) Higher; (AVAV) (ESV) (BLUE) Lower (more...)
EpiPen auto-injection epinephrine pens manufactured by Mylan NV pharmaceutical company for use by severe allergy sufferers are seen in Washington, U.S., August 24, 2016. REUTERS/Jim Bourg
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
(Reuters) - U.S. representatives Jason Chaffetz and Elijah Cummings of the House Committee on Oversight and Government Reform sent a letter to Mylan NV Chief Executive Heather Bresch on Monday asking for documents and communications related to the fast-increasing price of allergy auto-injector EpiPens.
Mylan said earlier it would launch the first generic version of EpiPen for $300, half the price of the branded product, in the drugmaker's second step in less than a week to counter a backlash over the product's steep price.
Chaffetz and Cummings, the committee's chairman and ranking member respectively, requested documents related to Mylan's revenue from sales of EpiPens since 2007, manufacturing costs and the amount the company receives from federal health care programs.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Ted Kerr)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Armed groups take control of Libyan town of Ben Jawad, close to major oil ports: officials
- EU fines Credit Agricole, HSBC, JPMorgan for Euribor fixing
- From smart toothbrushes to cancer, Philips bets big on software
Create E-mail Alert Related CategoriesReuters
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!